Current options for drug delivery to the spinal cord

Bibliography

• Watson C, Paxinos G, Kayalioglu G. The spinal cord: a christopher and dana reeve foundation text and atlas. Academic press; London: 2009
   Google Scholar
• Skyrme AD, Selmon GPF, Apthorp A. Common spinal disorders explained. Remedica; London: 2005
   Google Scholar
• Miller RG. Amyotrophic lateral sclerosis. Demos Medical Publishing; New York: 2010
   Google Scholar
• Morren JA, Galvez-Jimenez N. Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis. Expert Opin Investig Drugs 2012;21:297-320
   PubMed Web of Science ®Google Scholar
• Rabchevsky AG, Patel SP, Springer JE. Pharmacological interventions for spinal cord injury: where do we stand? How might we step forward? Pharmacol Ther 2011;132:15-29
   PubMed Web of Science ®Google Scholar
• Berry JD, Cudkowicz ME. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig (Lond) 2011;1:1375-89
   PubMedGoogle Scholar
• Hawryluk GW, Rowland J, Kwon BK, Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus 2008;25:E14
   PubMed Web of Science ®Google Scholar
• Bartanusz V, Jezova D, Alajajian B, The blood-spinal cord barrier: morphology and clinical implications. Ann Neurol 2011;70:194-206
   PubMed Web of Science ®Google Scholar
• Cardoso FL, Brites D, Brito MA. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev 2010;64:328-63
   PubMed Web of Science ®Google Scholar
• Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010;37:48-57
   PubMed Web of Science ®Google Scholar
• Bernacki J, Dobrowolska A, Nierwinska K, Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep 2008;60:600-22
   PubMed Web of Science ®Google Scholar
• Ahn SH, Park HW, Lee BS, Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms. Spine (Phila Pa 1976) 2003;28:341-6; discussion 46-7
   PubMed Web of Science ®Google Scholar
• Rintala DH, Holmes SA, Courtade D, Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil 2007;88:1547-60
   PubMed Web of Science ®Google Scholar
• Kilpatrick GJ, Smith TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev 2005;25:521-44
   PubMed Web of Science ®Google Scholar
• Bernard JM, Kick O, Bonnet F. Comparison of intravenous and epidural clonidine for postoperative patient-controlled analgesia. Anesth Analg 1995;81:706-12
   PubMed Web of Science ®Google Scholar
• Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage 2003;26:668-77
   PubMed Web of Science ®Google Scholar
• Satoh M, Minami M. Molecular pharmacology of the opioid receptors. Pharmacol Ther 1995;68:343-64
   PubMed Web of Science ®Google Scholar
• Kheder A, Nair KP. Spasticity: pathophysiology, evaluation and management. Pract Neurol 2012;12:289-98
   PubMedGoogle Scholar
• Brennan PM, Whittle IR. Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. Br J Neurosurg 2008;22:508-19
   PubMed Web of Science ®Google Scholar
• Richard I, Menei P. Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders. Acta Neurochir Suppl 2007;97:213-18
   PubMedGoogle Scholar
• Mullarkey T. Considerations in the treatment of spasticity with intrathecal baclofen. Am J Health Syst Pharm 2009;66:S14-22
   PubMed Web of Science ®Google Scholar
• Fenstermacher J, Gazendam J. Intra-arterial infusions of drugs and hyperosmotic solutions as ways of enhancing CNS chemotherapy. Cancer Treat Rep 1981;65(Suppl 2):27-37
   PubMedGoogle Scholar
• Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012;32:1959-72
   PubMed Web of Science ®Google Scholar
• Wang M, Etu J, Joshi S. Enhanced disruption of the blood brain barrier by intracarotid mannitol injection during transient cerebral hypoperfusion in rabbits. J Neurosurg Anesthesiol 2007;19:249-56
   PubMed Web of Science ®Google Scholar
• Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000;20:217-30
   PubMed Web of Science ®Google Scholar
• Erdlenbruch B, Schinkhof C, Kugler W, Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the rat brain. Br J Pharmacol 2003;139:685-94
   PubMed Web of Science ®Google Scholar
• Emerich DF, Dean RL, Osborn C, The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation. Clin Pharmacokinet 2001;40:105-23
   PubMed Web of Science ®Google Scholar
• Hynynen K. Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev 2008;60:1209-17
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron 2002;36:555-8
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Brain drug targeting and gene technologies. Jpn J Pharmacol 2001;87:97-103
   PubMedGoogle Scholar
• Garzon-Aburbeh A, Poupaert JH, Claesen M, A lymphotropic prodrug of L-dopa: synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)prop anoyl] propane-1,2,3-triol. J Med Chem 1986;29:687-91
   PubMed Web of Science ®Google Scholar
• Prokai L, Prokai-Tatrai K, Bodor N. Targeting drugs to the brain by redox chemical delivery systems. Med Res Rev 2000;20:367-416
   PubMed Web of Science ®Google Scholar
• Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 2001;46:247-79
   PubMed Web of Science ®Google Scholar
• Nonaka N, Farr SA, Kageyama H, Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins. J Pharmacol Exp Ther 2008;325:513-19
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003;3:90-105, 51
   PubMedGoogle Scholar
• Zhang Y, Pardridge WM. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther 2005;313:1075-81
   PubMed Web of Science ®Google Scholar
• Coloma MJ, Lee HJ, Kurihara A, Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 2000;17:266-74
   PubMed Web of Science ®Google Scholar
• Kounnas MZ, Moir RD, Rebeck GW, LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995;82:331-40
   PubMed Web of Science ®Google Scholar
• Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 2004;104:29-45
   PubMed Web of Science ®Google Scholar
• Liu Y, Wang CY, Kong XH, Novel multifunctional polyethylene glycol-transactivating-transduction protein-modified liposomes cross the blood-barrier after spinal cord spinal cord injury. J Drug Target 2010;18:420-9
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang S, Liao Z, PEGlated magnetic polymeric liposome anchored with TAT for delivery of drugs across the blood-spinal cord barrier. Biomaterials 2010;31:6589-96
   PubMed Web of Science ®Google Scholar
• Reukov V, Maximov V, Vertegel A. Proteins conjugated to poly(butyl cyanoacrylate) nanoparticles as potential neuroprotective agent. Biotechnol Bioeng 2011;108:243-52
   PubMed Web of Science ®Google Scholar
• Cho Y, Shi R, Borgens RB, Repairing the damaged spinal cord and brain with nanomedicine. Small 2008;4:1676-81
   PubMed Web of Science ®Google Scholar
• Kohane DS. Microparticles and nanoparticles for drug delivery. Biotechnol Bioeng 2007;96:203-9
   PubMed Web of Science ®Google Scholar
• Mastropietro DJ, Omidian H, Park K. Drug delivery applications for superporous hydrogels. Expert Opin Drug Deliv 2012;9:71-89
   PubMed Web of Science ®Google Scholar
• Mout R, Moyano DF, Rana S, Surface functionalization of nanoparticles for nanomedicine. Chem Soc Rev 2012;41:2539-44
   PubMed Web of Science ®Google Scholar
• Jiang W, Kim BYS, Rutka J, Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008;3:145-50
   PubMed Web of Science ®Google Scholar
• Yu Y, Ferrari R, Lattuada M, PLA-based nanoparticles with tunable hydrophobicity and degradation kinetics. J Polym Sci Polym Chem 2012;50:5191-200
   Web of Science ®Google Scholar
• Yoo JW, Mitragotri S. Polymer particles that switch shape in response to a stimulus. Proc Natl Acad Sci USA 2010;107:11205-10
   PubMed Web of Science ®Google Scholar
• Cerqueira SR, Silva BL, Oliveira JM, Multifunctionalized CMCht/PAMAM dendrimer nanoparticles modulate the cellular uptake by astrocytes and oligodendrocytes in primary cultures of glial cells. Macromol Biosci 2012;12:591-7
   PubMed Web of Science ®Google Scholar
• Wang YC, Wu YT, Huang HY, Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury. Biomaterials 2008;29:4546-53
   PubMed Web of Science ®Google Scholar
• Lunov O, Syrovets T, Loos C, Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. ACS Nano 2011;5:1657-69
   PubMed Web of Science ®Google Scholar
• Cho Y, Shi R, Ivanisevic A, Functional silica nanoparticle-mediated neuronal membrane sealing following traumatic spinal cord injury. J Neurosci Res 2010;88:1433-44
   PubMed Web of Science ®Google Scholar
• Kim YT, Caldwell JM, Bellamkonda RV. Nanoparticle-mediated local delivery of methylprednisolone after spinal cord injury. Biomaterials 2009;30:2582-90
   PubMed Web of Science ®Google Scholar
• Takenaga M, Ishihara T, Ohta Y, Nano PGE1 promoted the recovery from spinal cord injury-induced motor dysfunction through its accumulation and sustained release. J Control Release 2010;148:249-54
   PubMed Web of Science ®Google Scholar
• Menon PK, Muresanu DF, Sharma A, Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in following intoxication of engineered nanoparticles from metals. CNS Neurol Disord Drug Targets 2012;11:40-9
   PubMed Web of Science ®Google Scholar
• Baumann MD, Kang CE, Tator CH, Intrathecal delivery of a polymeric nanocomposite hydrogel after spinal cord injury. Biomaterials 2010;31:7631-9
   PubMed Web of Science ®Google Scholar
• Chvatal SA, Kim YT, Bratt-Leal AM, Spatial distribution and acute anti-inflammatory effects of Methylprednisolone after sustained local delivery to the contused spinal cord. Biomaterials 2008;29:1967-75
   PubMed Web of Science ®Google Scholar
• Kim H, Tator CH, Shoichet MS. Chitosan implants in the rat spinal cord: biocompatibility and biodegradation. J Biomed Mater Res A 2011;97A:395-404
   Web of Science ®Google Scholar
• Stanwick JC, Baumann MD, Shoichet MS. In vitro sustained release of bioactive anti-NogoA, a molecule in clinical development for treatment of spinal cord injury. Int J Pharm 2012;426:284-90
   PubMedGoogle Scholar
• Stanwick JC, Baumann MD, Shoichet MS. Enhanced neurotrophin-3 bioactivity and release from a nanoparticle-loaded composite hydrogel. J Control Release 2012;160:666-75
   PubMed Web of Science ®Google Scholar
• Goraltchouk A, Scanga V, Morshead CM, Incorporation of protein-eluting microspheres into biodegradable nerve guidance channels for controlled release. J Control Release 2006;110:400-7
   PubMed Web of Science ®Google Scholar
• Piotrowicz A, Shoichet MS. Nerve guidance channels as drug delivery vehicles. Biomaterials 2006;27:2018-27
   PubMed Web of Science ®Google Scholar
• Forloni G. Responsible nanotechnology development. J Nanopart Res 2012;14:1-17
   PubMedGoogle Scholar
• Harbaugh RE, Saunders RL, Reeder RF. Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery 1988;23:693-8
   PubMed Web of Science ®Google Scholar
• Simpson RK Jr. Mechanisms of action of intrathecal medications. Neurosurg Clin N Am 2003;14:353-64
   PubMed Web of Science ®Google Scholar
• Brill S, Gurman GM, Fisher A. A history of neuraxial administration of local analgesics and opioids. Eur J Anaesthesiol 2003;20:682-9
   PubMed Web of Science ®Google Scholar
• Lawson EF, Wallace MS. Advances in intrathecal drug delivery. Curr Opin Anaesthesiol 2012;25:572-6
   PubMed Web of Science ®Google Scholar
• Smith HS, Deer TR, Staats PS, Intrathecal drug delivery. Pain Physician 2008;11:S89-S104
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug delivery to the brain. J Cereb Blood Flow Metab 1997;17:713-31
   PubMed Web of Science ®Google Scholar
• Hayek SM, Deer TR, Pope JE, Intrathecal therapy for cancer and non-cancer pain. Pain Physician 2011;14:219-48
   PubMed Web of Science ®Google Scholar
• Erwin A, Gudesblatt M, Bethoux F, Intrathecal baclofen in multiple sclerosis: too little, too late? Mult Scler 2011;17:623-9
   PubMed Web of Science ®Google Scholar
• Belverud S, Mogilner A, Schulder M. Intrathecal pumps. Neurotherapeutics 2008;5:114-22
   PubMed Web of Science ®Google Scholar
• Ghafoor VL, Epshteyn M, Carlson GH, Intrathecal drug therapy for long-term pain management. Am J Health Syst Pharm 2007;64:2447-61
   PubMed Web of Science ®Google Scholar
• Cohen SP, Dragovich A. Intrathecal analgesia. Anesthesiol Clin 2007;25:863-82; viii
   PubMedGoogle Scholar
• Baumann MD, Kang CE, Stanwick JC, An injectable drug delivery platform for sustained combination therapy. J Control Release 2009;138:205-13
   PubMed Web of Science ®Google Scholar
• Perale G, Rossi F, Santoro M, Multiple drug delivery hydrogel system for spinal cord injury repair strategies. J Control Release 2012;159:271-80
   PubMed Web of Science ®Google Scholar
• Slaughter BV, Khurshid SS, Fisher OZ, Hydrogels in regenerative medicine. Adv Mater 2009;21:3307-29
   PubMed Web of Science ®Google Scholar
• Perale G, Rossi F, Sundstrom E, Hydrogels in spinal cord injury repair strategies. ACS Chem Neurosci 2011;2:366-45
   Google Scholar
• Lee H, McKeon RJ, Bellamkonda RV. Sustained delivery of thermostabilized chABC enhances axonal sprouting and functional recovery after spinal cord injury. Proc Natl Acad Sci USA 2010;107:3340-5
   PubMed Web of Science ®Google Scholar
• Mokarram N, Merchant A, Mukhatyar V, Effect of modulating macrophage phenotype on peripheral nerve repair. Biomaterials 2012;33:8793-801
   PubMed Web of Science ®Google Scholar
• Kubinova S, Horak D, Plichta Z, Highly superporous cholesterol-modified poly(2-hydroxyethyl methacrylate) scaffolds for spinal cord injury repair. J Biomed Mater Res A 2011;99A:618-29
   Web of Science ®Google Scholar
• Shoichet MS. Polymer scaffolds for biomaterials applications. Macromolecules 2010;43:581-91
   Web of Science ®Google Scholar
• Amoozgar Z, Rickett T, Park J, Semi-interpenetrating network of polyethylene glycol and photocrosslinkable chitosan as an in-situ forming nerve adhesive. Acta Biomater 2012;8:1849-58
   PubMed Web of Science ®Google Scholar
• Jain A, Kim YT, McKeon RJ, In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials 2006;27:497-504
   PubMed Web of Science ®Google Scholar
• Schaub NJ, Gilbert RJ. Controlled release of 6-aminonicotinamide from aligned, electrospun fibers alters astrocyte metabolism and dorsal root ganglia neurite outgrowth. J Neural Eng 2011;8:1-10
   Google Scholar
• Yang CY, Song B, Ao Y, Biocompatibility of amphiphilic diblock copolypeptide hydrogels in the central nervous system. Biomaterials 2009;30:2881-98
   PubMed Web of Science ®Google Scholar
• Wang Y, Lapitsky Y, Kang CE, Accelerated release of a sparingly soluble drug from an injectable hyaluronan–methylcellulose hydrogel. J Control Release 2009;140:218-23
   PubMed Web of Science ®Google Scholar
• Pritchard CD, O'Shea TM, Siegwart DJ, An injectable thiol-acrylate poly(ethylene glycol) hydrogel for sustained release of methylprednisolone sodium succinate. Biomaterials 2011;32:587-97
   PubMed Web of Science ®Google Scholar
• Kang CE, Poon PC, Tator CH, A new paradigm for local and sustained release of therapeutic molecules to the injured for neuroprotection and tissue repair. Tissue Eng A 2009;15:595-604
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang A, Shen W, Nanofibrous patches for spinal cord regeneration. Adv Funct Mater 2010;20:1443-0
   Google Scholar
• Varghese OP, Sun WL, Hilborn J, In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach. J Am Chem Soc 2009;131:8781-3
   PubMed Web of Science ®Google Scholar
• Anderson SB, Lin CC, Kuntzler DV, The performance of human mesenchymal stem cells encapsulated in cell-degradable polymer-peptide hydrogels. Biomaterials 2011;32:3564-74
   PubMed Web of Science ®Google Scholar
• Kubinova S, Horak D, Kozubenko N, The use of superporous Ac-CGGASIKVAVS-OH-modified PHEMA scaffolds to promote cell adhesion and the differentiation of human fetal neural precursors. Biomaterials 2010;31:5966-75
   PubMed Web of Science ®Google Scholar
• Macaya D, Ng KK, Spector M. Injectable collagen–genipin gel for the treatment of spinal cord injury: in vitro studies. Adv Funct Mater 2011;21:4788-97
   Web of Science ®Google Scholar
• Vulic K, Shoichet MS. Tunable growth factor delivery from injectable hydrogels for tissue engineering. J Am Chem Soc 2012;134:882-5
   PubMed Web of Science ®Google Scholar
• von Burkersroda F, Schedl L, Gopferich A. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 2002;23:4221-31
   PubMed Web of Science ®Google Scholar
• Muresanu DF, Sharma A, Tian ZR, Nanowired of antioxidant compound H-290/51 enhances neuroprotection in hyperthermia-induced neurotoxicity. CNS Neurol Disord Drug Targets 2012;11:50-64
   PubMed Web of Science ®Google Scholar
• Sharma HS. Early microvascular reactions and blood–spinal cord barrier disruption are instrumental in pathophysiology of spinal cord injury and repair: novel therapeutic strategies including nanowired drug delivery to enhance neuroprotectio. J Neural Transm 2011;118:155-76
   PubMed Web of Science ®Google Scholar
• Sharma HS, Ali SF, Dong W, Drug delivery to the spinalcord tagged with nanowire enhances neuroprotective efficacy and functional recovery following trauma to the rat spinal cord. Ann NY Acad Sci 2007;1122:197-218
   PubMed Web of Science ®Google Scholar
• Tian ZR, Sharma A, Nozari A, Nanowired to enhance neuroprotection in drug delivery spinal cord injury. CNS Neurol Disord Drug Targets 2012;11:86-95
   PubMed Web of Science ®Google Scholar
• Kwon BK, Okon E, Hillyer J, A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury. J Neurotrauma 2011;28:1545-88
   PubMed Web of Science ®Google Scholar
• Kwon BK, Okon EB, Plunet W, A systematic review of directly applied biologic therapies for acute spinal cord injury. J Neurotrauma 2011;28:1589-610
   PubMed Web of Science ®Google Scholar
• Tetzlaff W, Okon EB, Karimi-Abdolrezaee S, A systematic review of cellular transplantation therapies for spinal cord injury. J Neurotrauma 2011;28:1611-82
   PubMed Web of Science ®Google Scholar
• Hyatt AJT, Wang D, Kwok JC, Controlled release of chondroitinase ABC from fibrin gel reduces the level of inhibitory glycosaminoglycan chains in lesioned spinal cord. J Control Release 2010;147:24-9
   PubMed Web of Science ®Google Scholar
• Rossi F, Veglianese P, Santoro M, Sustained delivery of chondroitinase ABC from hydrogel system. J Funct Biomater 2012;3:199-208
   Google Scholar
• Koutsopoulos S, Unsworth LD, Nagai Y, Controlled release of functional proteins through designer self-assembling peptide nanofiber hydrogel scaffold. Proc Natl Acad Sci USA 2009;106:4623-8
   PubMed Web of Science ®Google Scholar
• Liu T, Xu J, Chan B, Sustained release of neurotrophin-3 and chondroitinase ABC from electrospun collagen nanofiber scaffold for spinal cord injury repair. J Biomed Mater Res A 2011;100A:236-42
   Web of Science ®Google Scholar
• Han QQ, Sun WJ, Lin H, Linear ordered collagen scaffolds loaded with collagen-binding brain-derived neurotrophic factor improve the recovery of spinal cord injury in rats. Tissue Eng A 2009;15:2927-35
   PubMed Web of Science ®Google Scholar
• Liang W, Han Q, Jin W, The promotion of neurological recovery in the rat spinal cord crushed injury model by collagen-binding BDNF. Biomaterials 2010;31:8634-41
   PubMed Web of Science ®Google Scholar
• Mehotra S, Lynam D, Maloney R, Time controlled protein release from layer-by-layer assembled multilayer functionalized agarose hydrogels. Adv Funct Mater 2010;20:247-58
   PubMed Web of Science ®Google Scholar
• Stokols S, Tuszynski MH. Freeze-dried agarose scaffolds with uniaxial channels stimulate and guide linear axonal growth following spinal cord injury. Biomaterials 2006;27:443-51
   PubMed Web of Science ®Google Scholar
• Burdick JA, Ward M, Liang E, Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. Biomaterials 2006;27:452-9
   PubMed Web of Science ®Google Scholar
• Hamann MCJ, Tator CH, Shoichet MS. Injectable intrathecal delivery system for localized administration of EGF and FGF-2 to the injured rat spinal cord. Exp Neurol 2005;194:106-19
   PubMed Web of Science ®Google Scholar